BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer’s Disease
August 05, 2021 08:00 ET
|
BioVie, Inc.
SANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug candidates for the treatment of...
BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
July 27, 2021 08:00 ET
|
BioVie, Inc.
SANTA MONICA, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and...
BioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
July 22, 2021 08:00 ET
|
BioVie, Inc.
SANTA MONICA, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and...
Basis for BioVie’s Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer’s Disease Published in Neurodegenerative Disease Management
July 16, 2021 08:00 ET
|
BioVie, Inc.
SANTA MONICA, Calif., July 16, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and...
BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
June 17, 2021 16:05 ET
|
BioVie, Inc.
SANTA MONICA, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"),a clinical-stage company developing innovative drug therapies for the treatment of liver...
BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix
June 11, 2021 08:00 ET
|
BioVie, Inc.
SANTA MONICA, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company") today announced the closing of its previously announced acquisition of the...
BioVie Hosting Research & Development Day
May 12, 2021 08:00 ET
|
BioVie, Inc.
SANTA MONICA, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver...
BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix
May 10, 2021 08:19 ET
|
BioVie, Inc.
SANTA MONICA, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for chronic debilitating...
BioVie to Present at 2021 B. Riley Securities’ Neuroscience Conference
April 28, 2021 07:00 ET
|
BioVie, Inc.
SANTA MONICA, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver...
BioVie Acquires Biopharma Assets from Privately Held NeurMedix
April 27, 2021 16:05 ET
|
BioVie, Inc.
Includes Pivotal Phase 3 Alzheimer’s Asset NE3107 Cuong V. Do Named CEO of The New BioVie Conference Call Scheduled for April 27, 2021 at 5:00PM EDT SANTA MONICA, Calif., April 27, 2021 ...